GlaxoSmithKline (GSK)

This sponsor has funded 101 studies across 53 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
2353 Finalised Yes No
2356 Finalised Yes Yes
2382 Finalised Yes No
2385 Ongoing Yes No
2388 Ongoing Yes No
2561 Ongoing Yes No
2628 Finalised Yes Yes
3310 Finalised Yes Yes
4093 Finalised Yes Yes
4126 Finalised Yes Yes
4129 Finalised Yes Yes
4584 Finalised Yes Yes
4851 Finalised Yes Yes
4966 Ongoing Yes No
5049 Finalised Yes Yes
5306 Finalised No No
5418 Ongoing Yes No
5568 Finalised Yes Yes
6186 Finalised Yes Yes
6189 Finalised Yes Yes
6229 Finalised Yes Yes
6234 Finalised Yes Yes
6242 Finalised Yes Yes
6441 Finalised No No
6577 Finalised Yes Yes
6655 Finalised Yes No
6969 Finalised Yes Yes
7305 Finalised Yes Yes
7361 Finalised Yes Yes
7761 Finalised Yes Yes
7766 Finalised Yes Yes
7953 Finalised Yes Yes
8093 Finalised Yes Yes
8375 Finalised Yes Yes
8615 Finalised No No
8618 Finalised No No
9868 Finalised Yes Yes
10224 Finalised Yes Yes
10316 Ongoing Yes No
10376 Finalised Yes No
10416 Finalised Yes No
10464 Finalised Yes Yes
11397 Finalised Yes Yes
11405 Finalised Yes Yes
11845 Finalised Yes Yes
12436 Finalised Yes No
12518 Finalised Yes Yes
12703 Finalised Yes Yes
13766 Finalised Yes Yes
13772 Ongoing Yes No
13908 Finalised Yes Yes
14947 Finalised Yes Yes
17720 Finalised Yes Yes
17926 Finalised Yes No
21362 Finalised Yes No
22912 Finalised Yes Yes
27806 Ongoing No No
28541 Ongoing Yes No
28551 Finalised Yes No
29407 Ongoing Yes No
29817 Finalised Yes Yes
30792 Finalised Yes No
33189 Planned Yes No
35147 Ongoing No No
35685 Finalised Yes Yes
37133 Finalised Yes No
37156 Ongoing Yes No
37605 Ongoing Yes No
38199 Planned No No
38374 Finalised Yes Yes
38633 Ongoing Yes No
38868 Planned Yes No
40313 Ongoing Yes No
40875 Finalised Yes Yes
42275 Ongoing Yes No
42373 Finalised Yes No
42517 Ongoing No No
42948 Ongoing Yes No
43810 Planned Yes No
43920 Ongoing Yes No
44701 Ongoing No No
44882 Ongoing Yes No
45288 Finalised Yes No
46386 Ongoing No No
46662 Ongoing Yes No
46820 Finalised Yes Yes
46888 Finalised Yes Yes
47006 Finalised No No
47064 Finalised Yes Yes
47885 Ongoing Yes No
49460 Planned No No
49554 Ongoing No No
103405 Planned Yes No
103974 Finalised Yes No
104070 Ongoing Yes No
105107 Ongoing Yes No
105374 Ongoing No No
105378 Ongoing No No
107073 Ongoing Yes No
107206 Ongoing No No
107230 Ongoing Yes No

PAS by Risk Management Plan (RMP) requirement

GlaxoSmithKline (GSK)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.